Indication: Mavixen, comprising Glecaprevir and Pibrentasvir at doses of 100 mg and 40 mg respectively, is indicated for treating chronic hepatitis C virus (HCV) infection in adults without cirrhosis or with compensated cirrhosis, including those coinfected with HIV-1.

Pharmacology: Glecaprevir inhibits HCV NS3/4A protease, while Pibrentasvir targets HCV NS5A protein. This combination therapy synergistically interferes with HCV RNA replication, impeding viral assembly and production.

Dosage and Administration: The recommended dosage of Mavixen is one tablet containing 100 mg of Glecaprevir and 40 mg of Pibrentasvir taken orally once daily with food. Treatment duration ranges from 8 to 16 weeks, adjusted based on prior treatment history and HCV genotype.

Interactions: Mavixen may interact with drugs affecting cytochrome P450 enzymes, particularly CYP3A and P-glycoprotein. Avoid concomitant use with strong CYP3A inducers or inhibitors, and use caution with antiretroviral medications and other CYP3A-metabolized drugs.

Side Effects: Common side effects include fatigue, headache, nausea, and insomnia, while others may experience diarrhea, pruritus, and elevated liver enzymes. Serious adverse effects like hepatotoxicity and bradycardia are rare but possible.

Precautions and Warnings:

• Monitor liver function during treatment, especially in patients with pre-existing liver disease.
• Use caution in patients taking drugs that slow heart rate or with cardiac conduction abnormalities due to the risk of bradycardia.
• Avoid in severe renal impairment or end-stage renal disease requiring hemodialysis.
• Inform patients about the risk of hepatitis B virus reactivation, particularly in those coinfected with HBV and HCV.

Overdose Effect: In case of overdose, provide supportive care. There’s no specific antidote; monitor for adverse reactions and initiate appropriate symptomatic treatment as needed.